Loading quotes...

Forecast

The analysts' average price target is €135.82 (-7.92%). The median is €135.82 (-7.92%).

Buy
  6
Hold
  17
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Novartis (ADR) has already paid €4.12 in dividends. The last payout was in March.

Financials

In the last quarter, Novartis (ADR) had revenue of €13.27bn and net profit of €1.06bn
(EUR) September 2026
YoY
Revenue 13.27bn 8.41%
Gross profit 10.08bn 9.33%
Net profit 1.06bn 68.31%
EBITDA 4.74bn 4.87%

Fundamentals

Metric Value
Market capitalization
€275.39bn
Number of shares
1.89bn
52-week high/low
€154.86 - €111.96
Dividend yield
2.85%
Dividends TTM
€4.12
Beta
0.41
P/E ratio
30.76
PEG ratio
-1.05
P/B ratio
8.11
P/S ratio
5.50

Company profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Name
Novartis (ADR)
CEO
Vasant Narasimhan
Headquarters Basel, bs
Switzerland
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
07/11/1996
Employees 75,267

Ticker symbols

Exchange Symbol
NYSE
NVS
Frankfurt
NOTA.F
Düsseldorf
NOTA.DU
London
0K9E.L
München
NOTA.MU
🍪

Parqet  uses cookies. Learn more